Ligand validation:1VZD

CB3: 10-PROPARGYL-5,8-DIDEAZAFOLIC ACID

CB3 is a Ligand Of Interest in 1VZD designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
1VZD_CB3_A_318	30%	5%	0.16	0.822	2.6	2.76	11	14	3	0	100%	1
1VZE_CB3_A_318	36%	6%	0.181	0.872	2.18	2.8	10	12	0	0	100%	1
1LCA_CB3_A_318	19%	7%	0.318	0.913	2.11	2.67	12	11	3	0	100%	1
1TVU_CB3_A_318	6%	10%	0.345	0.772	1.7	2.53	6	9	0	0	100%	1
1TVW_CB3_A_318	2%	3%	0.423	0.702	2.82	3.13	6	17	6	0	100%	1
1TVV_CB3_A_318	0%	11%	0.831	0.499	1.71	2.46	5	7	0	0	100%	1
6NNR_CB3_B_302	93%	19%	0.076	0.97	1.19	2.25	3	8	0	0	100%	1
2AAZ_CB3_E_2551	92%	5%	0.081	0.973	2.5	2.75	16	15	0	0	100%	0.25
4GEV_CB3_B_802	87%	25%	0.081	0.954	1.15	1.91	3	10	0	0	100%	1
2FTO_CB3_X_266	82%	17%	0.087	0.943	1.58	2	6	6	1	0	100%	1
4EIL_CB3_G_702	76%	9%	0.105	0.941	1.96	2.43	8	13	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.